Neuroplast appoints Sanquin's Dr. Pieter de Geus to its supervisory board
News
Neuroplast, a Dutch clinical stage biotech focusing on cell-based treatments for neurological disorders, announced the appointment of Dr. Pieter de Geus, Managing Director of Sanquin Health Solutions, and prof. emeritus and TiGenix co-founder Dr. Frank Luyten to its supervisory board.
Luyten and De Geus bring a wealth of experience in both clinical and regulatory affairs and technology and manufacturing. Their expertise enables Neuroplast to further develop cell-based treatments that improve and extend the lives of patients with inflammation-driven neurological disorders like Traumatic Spinal Cord Injury.
